WHO Targets Single Injection TB Prevention by 2026

The World Health Organization (WHO) has announced ambitious new targets aimed at revolutionizing tuberculosis (TB) treatment by introducing long-acting injectable medicines. These new guidelines, published on October 28, 2026, propose that preventive treatment could be administered through a single injection, while treatment for active TB should ideally be completed within four months and require no more than three healthcare visits.

Historically, TB treatment has required patients to take multiple medications daily for several months, a regimen that can be particularly challenging for those facing socioeconomic barriers, long travel distances to healthcare facilities, or adverse side effects. Interruptions in treatment can lead to poorer health outcomes and contribute to drug resistance, making the need for innovative solutions urgent.

The WHO's new regimen profiles outline specific goals for both preventive and active TB treatment. Preventive measures are aimed at individuals with TB infection but without active disease, while treatment regimens target those diagnosed with active TB. The proposed injectable medicines are expected to match or exceed the effectiveness and safety of current oral treatments, thus providing a viable alternative for patients.

This initiative is especially critical for India, which bears the largest share of the global TB burden. According to the WHO's Global Tuberculosis Report 2025, India accounted for approximately 25% of the estimated 10.7 million global TB cases in 2024. The National TB Elimination Programme (NTEP) in India has been working to enhance early detection and treatment access, but the lengthy treatment duration often poses significant challenges for patients, particularly those from economically disadvantaged backgrounds.

While the WHO's announcement sets the stage for future developments in TB treatment, it is essential to note that these injectable options are still in the early stages of clinical development. Their effectiveness and safety must be validated through rigorous trials before they can be integrated into standard care. As India continues to grapple with high TB rates, the successful implementation of these long-acting injectables could transform treatment accessibility and adherence, ultimately improving public health outcomes.